PEPG
PepGen Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.70
+3.85%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +25.5%
- EBIT
- +25.8%
- EPS
- +49.3%
- Free cash flow
- +23.3%
- Operating cash flow
- +23.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +36.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +1.0%
- EBIT
- +4.2%
- Net income
- +0.4%
- EPS
- +25.6%
- Free cash flow
- +1.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026